You are right too!

Journal of Clinical Investigation

Volumn 115, Issue 8, 2005, Pages 2072-2075

  Witztum, Joseph L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CD36 ANTIGEN; CLASS A SCAVENGER RECEPTOR; GENE PRODUCT; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG;

AORTA; AORTA MACROPHAGE; AORTA VALVE DISEASE; ATHEROGENESIS; ATHEROSCLEROSIS; FOAM CELL; HUMAN; LIPID STORAGE; MACROPHAGE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIGENS, CD36; AORTIC VALVE; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; FOAM CELLS; GENE DELETION; HUMANS; LIPOPROTEINS, LDL; MICE; MICE, KNOCKOUT; RECEPTORS, IMMUNOLOGIC; RECEPTORS, SCAVENGER; SCAVENGER RECEPTORS, CLASS A;

EID: 23644458916     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI26130     Document Type: Review

References (25)

1. Moore, K.J., et al. 2005. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J. Clin. Invest 115:2192-2201. doi:10.1172/JCI24061.
2. Suzuki, H., et al. 1997. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 386:292-296.
3. Babaev, V.R., et al. 2000. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Arterioscler. Thromb. Vasc. Biol. 20:2593-2599.
4. Febbraio, M., et al. 2000. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105:1049-1056.
5. Febbraio, M., Guy, E., and Silverstein, R.L. 2004. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24:2333-2338.
6. Freigang, S., Hörkkö, S., Miller, E., Witztum, J.L., and Palinski, W. 1998. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18:1972-1982.
7. Skalen, K., et al. 2002. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 417:750-754.
8. VanderLaan, P.A., Reardon, C.A., and Getz, G.S. 2004. Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators [review]. Arterioscler. Thromb. Vasc. Biol. 24:12-22.
9. Van Eck, M., Bos, I.S., Hildebrand, R.B., Van Rij, B.T., and van Berkel, T.J. 2004. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Am. J. Pathol. 165:785-794.
10. Herz, J., and Hui, D.Y. 2004. Lipoprotein receptors in the vascular wall. Curr. Opin. Lipidol. 15:175-181.
11. Greaves, D.R., and Gordon, S. 2005. Thematic review series: the immune system and atherogenesis. Recent insights into the biology of macrophage scavenger receptors. J. Lipid Res. 46:11-20.
12. Yoshida, H., Quehenberger, O., Kondratenko, N., Green, S., and Steinberg, D. 1998. Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages. Arterioscler. Thromb. Vasc. Biol. 18:794-802.
13. Miller, Y.I., et al. 2003. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J. Biol. Chem. 278:1561-1568.
14. Liang, C.P., et al. 2004. Increased CD36 protein as a response to defective insulin signaling in macrophages. J. Clin. Invest. 113:764-773. doi:10.1172/JCI200419528.
15. Li, A.C., and Glass, C.K. 2002. The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 8:1235-1242.
16. Kunjathoor, V.V., et al. 2002. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277:49982-49988.
17. Khoo, J.C., Miller, E., Pio, F., Steinberg, D., and Witztum, J.L. 1992. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler. Thromb. Vasc. Biol. 12:1258-1266.
18. Schissel, S.L., et al. 1998. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lympoproteins at neutral pH. Implications for atherosclerotic lesion development. J. Biol. Chem. 273:2738-2746.
19. Griffith, R.L., Virella, G.T., Stevenson, H.C., and Lopes-Virella, M.F. 1988. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J. Exp. Med. 168:1041-1059.
20. Yeh, M., et al. 2004. Role for sterol regulatory element-binding protein in activation of endothelial cells by phospholipid oxidation products. Circ. Res. 95:780-788.
21. Kruth, H.S., et al. 2005. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem. 280:2352-2360.
22. Lindqvist, P., Ostlund-Lindqvist, A.M., Witztum, J.L., Steinberg, D., and Little, J.A. 1983. The role of lipoprotein lipase in the metabolism of triglyceride-rich lipoproteins by macrophages. J. Biol. Chem. 258:9086-9092.
23. Tall, A.R. 2003. Role of ABCA1 in cellular cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 23:710-711.
24. Hoebe, K., et al. 2005. CD36 is a sensor of diacylglycerides. Nature. 433:523-527.
25. Kunjathoor, V.V., Tseng, A.A., Medeiros, L.A., Khan, T., and Moore, K.J. 2004. beta-Amyloid promotes accumulation of lipid peroxides by inhibiting CD36-mediated clearance of oxidized lipoproteins. J. Neuroinflammation. 1:23. doi:10.1186/1742-2094-1-23.